Literature DB >> 24286589

Modeling human neurological disorders with induced pluripotent stem cells.

Yoichi Imaizumi1, Hideyuki Okano.   

Abstract

Human induced pluripotent stem (iPS) cells obtained by reprogramming technology are a source of great hope, not only in terms of applications in regenerative medicine, such as cell transplantation therapy, but also for modeling human diseases and new drug development. In particular, the production of iPS cells from the somatic cells of patients with intractable diseases and their subsequent differentiation into cells at affected sites (e.g., neurons, cardiomyocytes, hepatocytes, and myocytes) has permitted the in vitro construction of disease models that contain patient-specific genetic information. For example, disease-specific iPS cells have been established from patients with neuropsychiatric disorders, including schizophrenia and autism, as well as from those with neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. A multi-omics analysis of neural cells originating from patient-derived iPS cells may thus enable investigators to elucidate the pathogenic mechanisms of neurological diseases that have heretofore been unknown. In addition, large-scale screening of chemical libraries with disease-specific iPS cells is currently underway and is expected to lead to new drug discovery. Accordingly, this review outlines the progress made via the use of patient-derived iPS cells toward the modeling of neurological disorders, the testing of existing drugs, and the discovery of new drugs. The production of human induced pluripotent stem (iPS) cells from the patients' somatic cells and their subsequent differentiation into specific cells have permitted the in vitro construction of disease models that contain patient-specific genetic information. Furthermore, innovations of gene-editing technologies on iPS cells are enabling new approaches for illuminating the pathogenic mechanisms of human diseases. In this review article, we outlined the current status of neurological diseases-specific iPS cell research and described recently obtained knowledge in the form of actual examples.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  Parkinson's disease; human disease model; induced pluripotent stem cells; neurological disorders

Mesh:

Year:  2013        PMID: 24286589     DOI: 10.1111/jnc.12625

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  38 in total

1.  Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synaptic Transmission Defects Caused by Heterozygous Mutations in NRXN1.

Authors:  ChangHui Pak; Tamas Danko; Yingsha Zhang; Jason Aoto; Garret Anderson; Stephan Maxeiner; Fei Yi; Marius Wernig; Thomas C Südhof
Journal:  Cell Stem Cell       Date:  2015-08-13       Impact factor: 24.633

2.  Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice.

Authors: 
Journal:  Nat Neurosci       Date:  2017-03-20       Impact factor: 24.884

Review 3.  Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.

Authors:  Lei Cao; Lan Tan; Teng Jiang; Xi-Chen Zhu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2014-08-23       Impact factor: 5.590

Review 4.  Three-Dimensional Models of the Human Brain Development and Diseases.

Authors:  Mehdi Jorfi; Carla D'Avanzo; Doo Yeon Kim; Daniel Irimia
Journal:  Adv Healthc Mater       Date:  2017-08-28       Impact factor: 9.933

5.  iPSCs-derived nerve-like cells from familial Alzheimer's disease PSEN 1 E280A reveal increased amyloid-beta levels and loss of the Y chromosome.

Authors:  Miguel Mendivil-Perez; Carlos Velez-Pardo; Kenneth S Kosik; Francisco Lopera; Marlene Jimenez-Del-Rio
Journal:  Neurosci Lett       Date:  2019-03-20       Impact factor: 3.046

Review 6.  Biomanufacturing for clinically advanced cell therapies.

Authors:  Ayesha Aijaz; Matthew Li; David Smith; Danika Khong; Courtney LeBlon; Owen S Fenton; Ronke M Olabisi; Steven Libutti; Jay Tischfield; Marcela V Maus; Robert Deans; Rita N Barcia; Daniel G Anderson; Jerome Ritz; Robert Preti; Biju Parekkadan
Journal:  Nat Biomed Eng       Date:  2018-06-11       Impact factor: 25.671

Review 7.  Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines.

Authors:  Surya K Mallapragada; Timothy M Brenza; JoEllyn M McMillan; Balaji Narasimhan; Donald S Sakaguchi; Anup D Sharma; Svitlana Zbarska; Howard E Gendelman
Journal:  Nanomedicine       Date:  2015-01-31       Impact factor: 5.307

Review 8.  Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.

Authors:  Fernanda Martins Lopes; Ivi Juliana Bristot; Leonardo Lisbôa da Motta; Richard B Parsons; Fabio Klamt
Journal:  Neuromolecular Med       Date:  2017-07-18       Impact factor: 3.843

Review 9.  Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson's, Alzheimer's, and psychiatric diseases.

Authors:  Haruhiro Higashida; Shigeru Yokoyama; Chiharu Tsuji; Shin-Ichi Muramatsu
Journal:  J Physiol Sci       Date:  2016-06-11       Impact factor: 2.781

Review 10.  Modeling Ischemic Stroke In Vitro: Status Quo and Future Perspectives.

Authors:  Paul M Holloway; Felicity N E Gavins
Journal:  Stroke       Date:  2016-01-07       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.